The World Health Organization (WHO) report that at least 19 million yearly deaths are from cardiometabolic disorders – an umbrella term for cardiovascular disease and conditions such as metabolic syndrome and type 2 diabetes.
Germany based Boehringer Ingelheim has committed up to €250 million ($300 million) to work with Gubra on obesity treatments. As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.